Esperion Therapeutics Inc
ESPR3.880USD
-0.030-0.77%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
797.07MMarket Cap
LossP/E TTM
More Details of Esperion Therapeutics Inc Company
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Esperion Therapeutics Inc Info
Ticker SymbolESPR
Company nameEsperion Therapeutics Inc
IPO dateJun 24, 2013
CEOKoenig (Sheldon L)
Number of employees304
Security typeOrdinary Share
Fiscal year-endJun 24
Address3891 Ranchero Drive, Suite 150
CityANN ARBOR
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code48108
Phone17348873903
Websitehttps://www.esperion.com/
Ticker SymbolESPR
IPO dateJun 24, 2013
CEOKoenig (Sheldon L)
Company Executives of Esperion Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sheldon L. Koenig
Mr. Sheldon L. Koenig
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
201.56K
-48244.00%
Mr. Stephen C. Rocamboli, J.D.
Mr. Stephen C. Rocamboli, J.D.
Independent Director
Independent Director
69.26K
+33000.00%
Mr. Benjamin (Ben) Halladay
Mr. Benjamin (Ben) Halladay
Chief Financial Officer
Chief Financial Officer
69.12K
-7337.00%
Ms. Tracy M. Woody
Ms. Tracy M. Woody
Independent Director
Independent Director
33.57K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Independent Director
Independent Director
5.28K
+5280.00%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Independent Director
Independent Director
--
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Mr. Benjamin O. Looker, Esq.
Mr. Benjamin O. Looker, Esq.
General Counsel
General Counsel
--
--
Mr. J. Martin (Marty) Carroll
Mr. J. Martin (Marty) Carroll
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sheldon L. Koenig
Mr. Sheldon L. Koenig
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
201.56K
-48244.00%
Mr. Stephen C. Rocamboli, J.D.
Mr. Stephen C. Rocamboli, J.D.
Independent Director
Independent Director
69.26K
+33000.00%
Mr. Benjamin (Ben) Halladay
Mr. Benjamin (Ben) Halladay
Chief Financial Officer
Chief Financial Officer
69.12K
-7337.00%
Ms. Tracy M. Woody
Ms. Tracy M. Woody
Independent Director
Independent Director
33.57K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Independent Director
Independent Director
5.28K
+5280.00%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.64%
The Vanguard Group, Inc.
5.06%
Two Seas Capital LP
4.08%
Wasatch Global Investors Inc
2.95%
PenderFund Capital Management, Ltd.
2.79%
Other
79.48%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.64%
The Vanguard Group, Inc.
5.06%
Two Seas Capital LP
4.08%
Wasatch Global Investors Inc
2.95%
PenderFund Capital Management, Ltd.
2.79%
Other
79.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.95%
Investment Advisor/Hedge Fund
12.40%
Hedge Fund
8.62%
Research Firm
3.75%
Private Equity
0.93%
Individual Investor
0.59%
Venture Capital
0.31%
Bank and Trust
0.18%
Pension Fund
0.12%
Other
52.15%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
380
113.24M
47.37%
-38.58M
2025Q3
368
106.10M
76.75%
+4.05M
2025Q2
372
102.00M
77.57%
-15.99M
2025Q1
392
118.00M
85.10%
-50.37M
2024Q4
404
131.56M
87.79%
+410.17K
2024Q3
398
131.22M
89.54%
-7.94M
2024Q2
383
138.98M
78.00%
+11.51M
2024Q1
368
127.28M
52.86%
+27.17M
2023Q4
356
72.92M
91.16%
-5.70M
2023Q3
377
78.62M
90.15%
+1.03M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
13.47M
5.64%
+20.18K
+0.15%
Sep 30, 2025
The Vanguard Group, Inc.
12.09M
5.06%
+375.62K
+3.21%
Sep 30, 2025
Two Seas Capital LP
9.75M
4.08%
-205.25K
-2.06%
Sep 30, 2025
Wasatch Global Investors Inc
7.06M
2.95%
-3.28M
-31.71%
Sep 30, 2025
PenderFund Capital Management, Ltd.
6.68M
2.79%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
4.75M
1.99%
+167.41K
+3.65%
Sep 30, 2025
State Street Investment Management (US)
4.48M
1.87%
+720.11K
+19.16%
Sep 30, 2025
Two Sigma Investments, LP
4.16M
1.74%
+238.00K
+6.07%
Sep 30, 2025
Meditor Capital Management Limited
3.79M
1.59%
--
--
Sep 30, 2024
Nuveen LLC
3.63M
1.52%
+3.21M
+759.96%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.17%
State Street SPDR S&P Pharmaceuticals ETF
1.01%
Invesco NASDAQ Future Gen 200 ETF
0.72%
VictoryShares Small Cap Free Cash Flow ETF
0.37%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco RAFI US 1500 Small-Mid ETF
0.08%
Principal U.S. Small-Cap ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.06%
Vanguard US Momentum Factor ETF
0.04%
View more
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.17%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.01%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.72%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.37%
iShares Micro-Cap ETF
Proportion0.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.1%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.08%
Principal U.S. Small-Cap ETF
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
Vanguard US Momentum Factor ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Esperion Therapeutics Inc?
The top five shareholders of Esperion Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A. holds 13.47M shares, accounting for 5.64% of the total shares.
The Vanguard Group, Inc. holds 12.09M shares, accounting for 5.06% of the total shares.
Two Seas Capital LP holds 9.75M shares, accounting for 4.08% of the total shares.
Wasatch Global Investors Inc holds 7.06M shares, accounting for 2.95% of the total shares.
PenderFund Capital Management, Ltd. holds 6.68M shares, accounting for 2.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 13.47M shares, accounting for 5.64% of the total shares.
The Vanguard Group, Inc. holds 12.09M shares, accounting for 5.06% of the total shares.
Two Seas Capital LP holds 9.75M shares, accounting for 4.08% of the total shares.
Wasatch Global Investors Inc holds 7.06M shares, accounting for 2.95% of the total shares.
PenderFund Capital Management, Ltd. holds 6.68M shares, accounting for 2.79% of the total shares.
What are the top three shareholder types of Esperion Therapeutics Inc?
The top three shareholder types of Esperion Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Two Seas Capital LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Two Seas Capital LP
How many institutions hold shares of Esperion Therapeutics Inc (ESPR)?
As of 2025Q4, 380 institutions hold shares of Esperion Therapeutics Inc, with a combined market value of approximately 113.24M, accounting for 47.37% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -29.38%.
What is the biggest source of revenue for Esperion Therapeutics Inc?
In --, the -- business generated the highest revenue for Esperion Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
